Compare
Atea Pharmaceuticals, Inc. vs Omeros Corp vs Prothena Corp Public Ltd Co vs ARS Pharmaceuticals, Inc.
| Latest fiscal year | Atea Pharmaceuticals, Inc. AVIR | Omeros Corp OMER | Prothena Corp Public Ltd Co PRTA | ARS Pharmaceuticals, Inc. SPRY |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | $9.68M | $84.28M |
| Revenue growth (YoY) | n/a | n/a | -92.8% | -5.5% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | n/m | -212.9% |
| Net margin | n/a | n/a | n/m | -203.3% |
| Net income | -$158.35M | -$3.35M | -$244.09M | -$171.30M |
| EPS (Diluted) | -$1.94 | -$0.05 | -$4.53 | -$1.74 |
| Operating cash flow | -$132.03M | -$116.09M | -$163.58M | -$170.87M |
| Free cash flow | n/a | -$116.16M | n/a | -$171.21M |
| Cash & equivalents | $95.71M | $9.66M | $307.53M | $41.32M |
| Total assets | $315.22M | $325.63M | $326.80M | $327.65M |
| Total liabilities | $39.78M | n/a | $46.33M | $213.39M |
| Shareholders' equity | $275.43M | -$121.23M | $280.47M | $114.26M |
| Return on year-end equity | -57.5% | n/a | -87.0% | -149.9% |
| Shares outstanding | 78.13M | 71.67M | 53.83M | 99.29M |
Revenue, most recent five fiscal years
| Fiscal year | Atea Pharmaceuticals, Inc. | Omeros Corp | Prothena Corp Public Ltd Co | ARS Pharmaceuticals, Inc. |
|---|---|---|---|---|
| Latest | $351.37M Ended 2021-12-31 | $73.81M Ended 2020-12-31 | $9.68M Ended 2025-12-31 | $84.28M Ended 2025-12-31 |
| 1 year earlier | $48.63M Ended 2020-12-31 | $111.81M Ended 2019-12-31 | $135.16M Ended 2024-12-31 | $89.15M Ended 2024-12-31 |
| 2 years earlier | n/a | $29.87M Ended 2018-12-31 | $91.37M Ended 2023-12-31 | $30.0K Ended 2023-12-31 |
| 3 years earlier | n/a | $64.83M Ended 2017-12-31 | $53.91M Ended 2022-12-31 | $1.32M Ended 2022-12-31 |
| 4 years earlier | n/a | $41.62M Ended 2016-12-31 | $200.58M Ended 2021-12-31 | $5.51M Ended 2021-12-31 |